Evaluation of miR137 gene expression on the survival rate of patients undergoing colorectal surgery with a history of neoadjuvant therapy

Résumé fourni par la source

Introduction: More than 400 colorectal tissues, including colorectal adenomas and cancers, and a panel of six CRC cell lines were used to study the epigenetic regulation of miR-137. Material and Methods: We go over miR-137's epigenetic control and how it affects the development of colorectal cancer. Six CRC cell lines, 50 colorectal tissues, 21 healthy individuals' normal colonic mucosa (N-N), 160 primary CRC tissues, and their corresponding normal mucosa (N-C), as well as 68 adenomas, were used to determine the methylation status of the miR-137 CpG island. We examined the expression of miR-137 using TaqMan RT-PCR and in situ hybridization. Results: MiR-137 was only expressed in colonic epithelial cells, which cover the entire colonic crypt, in normal colonic mucosa. However, none of the adenomatous and CRC samples exhibited miR-137 expression, supporting our finding that miR-137 is silenced in the majority of colonic neoplastic tissues. As a result of our discovery that CpG island methylation causes miR-137 to be epigenetically silenced in CRC, we then carried out functional studies to see if miR-137 had tumor-suppressive properties in vitro after transfecting CRC cell lines with miR-137 precursor. Conclusion: In conclusion, this study first explains that miR-137 acts as a tumor suppressor in the colon, is frequently silenced in CRC through promoter hypermethylation, and its restoration inhibits cell proliferation in vitro.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.